VDR agonists induce in vivo up-regulation of ILT3 on M-DCs and P-DCs in psoriatic lesions. (A) Skin biopsies from untreated psoriatic lesions, psoriatic plaques treated for 30 days with calcipotriol, and psoriatic plaques treated for 8 or 20 days with mometazone furoate were stained with anti-ILT3 mAb and counterstained with hematoxylin, as described in “Materials and methods.” Original magnification × 200, except top left panel (× 50); e indicates epidermis; d, dermis. (B) Noncounterstained serial sections from calcipotriol-treated psoriatic lesions shown in panel A stained with anti-CD1a, anti-CD123, and anti-ILT3. Original magnification × 100. (C) Expression of ILT3 in M-DCs and P-DCs from the calcipotriol-treated psoriatic lesions shown in panel A. Sections were stained with anti-ILT3 and anti-CD11c or anti-CD123, respectively, and analyzed by confocal microscopy. Merged stainings are shown in the right panels. The results refer to analysis of 1 representative patient out of 5 examined.